Immune-related adverse events, such as colitis, can be a consequence of anti-PD-1 therapy.50 To assess for such events, anti-PD-1 and/or Nb-Fc1B treated mice were subjected to a thorough evaluation of gut inflammation by histological examination. This evidence concerns the gene PDCD1 and colitis.